FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1909306097> ?p ?o ?g. }

• W1909306097 endingPage "1613" @default.
• W1909306097 startingPage "1602" @default.
• W1909306097 abstract "During the last decade, the Eastern Cooperative Oncology Group (ECOG) has studied a series of combination chemotherapy regimens in metastatic (stage IV) non-small-cell lung cancer (NSCLC). In January 1984, the ECOG activated a randomized study, EST 1583, which concluded the evaluation of combination regimens in phase III trials and initiated the evaluation of single agents exclusively in previously untreated patients. The treatment regimens in EST 1583 consisted of: (1) mitomycin, vinblastine, and cisplatin (MVP); (2) vinblastine and cisplatin (VP); (3) MVP alternating with the regimen cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP); (4) carboplatin followed by the MVP regimen at the time of progression; and (5) iproplatin followed by MVP at the time of progression. From January 1984 to July 1985, 743 patients were entered on this trial and 699 fulfilled the eligibility requirements. The following objective response rates (complete plus partial remissions) were observed: first-line MVP, 20%; VP, 13%; MVP/CAMP, 13%; carboplatin, 9%; iproplatin, 6%; and second-line MVP, 6%. First-line MVP produced a significantly higher response rate than the other treatments (P = .03) adjusted for prognostic variables. Using analyses that were adjusted for prognostic covariates, survival for patients treated on a given regimen was compared with survival for all remaining patients. These analyses showed that treatment with carboplatin was associated with longer survival (median survival time, 31.7 weeks; P = .008) while initial treatment with MVP was associated with a trend for shorter survival (median survival time, 22.7 weeks; P = .09). It should be noted that none of these regimens appear to have produced a clinically meaningful prolongation of survival. Similar analyses evaluating time to progression disclosed that carboplatin-treated patients had a significantly longer time to progression (median time to progression, 29 weeks) than all remaining patients (P = .01). Life-threatening and lethal toxicities (toxicity grades 4 and 5) were greater on the combination regimens than on the single agents (P less than .0001). Based on these results, current group-wide ECOG trials in stage IV NSCLC consist of randomized phase II trials evaluating single agents." @default.
• W1909306097 created "2016-06-24" @default.
• W1909306097 creator A5007826187 @default.
• W1909306097 creator A5009095405 @default.
• W1909306097 creator A5024343309 @default.
• W1909306097 creator A5027803713 @default.
• W1909306097 creator A5050073720 @default.
• W1909306097 creator A5057026118 @default.
• W1909306097 creator A5058502526 @default.
• W1909306097 creator A5073181974 @default.
• W1909306097 creator A5077630952 @default.
• W1909306097 creator A5071020599 @default.
• W1909306097 date "1989-11-01" @default.
• W1909306097 modified "2023-10-12" @default.
• W1909306097 title "Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group." @default.
• W1909306097 cites W12501893 @default.
• W1909306097 cites W1755983531 @default.
• W1909306097 cites W1856648916 @default.
• W1909306097 cites W1922104747 @default.
• W1909306097 cites W1975549289 @default.
• W1909306097 cites W2059563719 @default.
• W1909306097 cites W2076668534 @default.
• W1909306097 cites W2178828310 @default.
• W1909306097 cites W2201267472 @default.
• W1909306097 cites W2260635323 @default.
• W1909306097 cites W2264219837 @default.
• W1909306097 cites W2291356857 @default.
• W1909306097 cites W2411986908 @default.
• W1909306097 cites W2416059068 @default.
• W1909306097 cites W2433503088 @default.
• W1909306097 cites W2440265926 @default.
• W1909306097 cites W2444365962 @default.
• W1909306097 doi "https://doi.org/10.1200/jco.1989.7.11.1602" @default.
• W1909306097 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2553879" @default.
• W1909306097 hasPublicationYear "1989" @default.
• W1909306097 type Work @default.
• W1909306097 sameAs 1909306097 @default.
• W1909306097 citedByCount "312" @default.
• W1909306097 countsByYear W19093060972012 @default.
• W1909306097 countsByYear W19093060972013 @default.
• W1909306097 countsByYear W19093060972014 @default.
• W1909306097 countsByYear W19093060972016 @default.
• W1909306097 countsByYear W19093060972017 @default.
• W1909306097 countsByYear W19093060972019 @default.
• W1909306097 crossrefType "journal-article" @default.
• W1909306097 hasAuthorship W1909306097A5007826187 @default.
• W1909306097 hasAuthorship W1909306097A5009095405 @default.
• W1909306097 hasAuthorship W1909306097A5024343309 @default.
• W1909306097 hasAuthorship W1909306097A5027803713 @default.
• W1909306097 hasAuthorship W1909306097A5050073720 @default.
• W1909306097 hasAuthorship W1909306097A5057026118 @default.
• W1909306097 hasAuthorship W1909306097A5058502526 @default.
• W1909306097 hasAuthorship W1909306097A5071020599 @default.
• W1909306097 hasAuthorship W1909306097A5073181974 @default.
• W1909306097 hasAuthorship W1909306097A5077630952 @default.
• W1909306097 hasConcept C126322002 @default.
• W1909306097 hasConcept C141071460 @default.
• W1909306097 hasConcept C143998085 @default.
• W1909306097 hasConcept C2776256026 @default.
• W1909306097 hasConcept C2776694085 @default.
• W1909306097 hasConcept C2776907518 @default.
• W1909306097 hasConcept C2777132456 @default.
• W1909306097 hasConcept C2778239845 @default.
• W1909306097 hasConcept C2778336483 @default.
• W1909306097 hasConcept C2781413609 @default.
• W1909306097 hasConcept C2781451048 @default.
• W1909306097 hasConcept C71924100 @default.
• W1909306097 hasConcept C90924648 @default.
• W1909306097 hasConceptScore W1909306097C126322002 @default.
• W1909306097 hasConceptScore W1909306097C141071460 @default.
• W1909306097 hasConceptScore W1909306097C143998085 @default.
• W1909306097 hasConceptScore W1909306097C2776256026 @default.
• W1909306097 hasConceptScore W1909306097C2776694085 @default.
• W1909306097 hasConceptScore W1909306097C2776907518 @default.
• W1909306097 hasConceptScore W1909306097C2777132456 @default.
• W1909306097 hasConceptScore W1909306097C2778239845 @default.
• W1909306097 hasConceptScore W1909306097C2778336483 @default.
• W1909306097 hasConceptScore W1909306097C2781413609 @default.
• W1909306097 hasConceptScore W1909306097C2781451048 @default.
• W1909306097 hasConceptScore W1909306097C71924100 @default.
• W1909306097 hasConceptScore W1909306097C90924648 @default.
• W1909306097 hasIssue "11" @default.
• W1909306097 hasLocation W19093060971 @default.
• W1909306097 hasLocation W19093060972 @default.
• W1909306097 hasOpenAccess W1909306097 @default.
• W1909306097 hasPrimaryLocation W19093060971 @default.
• W1909306097 hasRelatedWork W1807302916 @default.
• W1909306097 hasRelatedWork W2013653877 @default.
• W1909306097 hasRelatedWork W2058121546 @default.
• W1909306097 hasRelatedWork W2104620569 @default.
• W1909306097 hasRelatedWork W2170498496 @default.
• W1909306097 hasRelatedWork W2363732038 @default.
• W1909306097 hasRelatedWork W2388730008 @default.
• W1909306097 hasRelatedWork W2398012384 @default.
• W1909306097 hasRelatedWork W4231341789 @default.
• W1909306097 hasRelatedWork W2125019270 @default.
• W1909306097 hasVolume "7" @default.
• W1909306097 isParatext "false" @default.

• next